These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 30201787)

  • 41. Combining immunotherapies for the treatment of prostate cancer.
    Redman JM; Gulley JL; Madan RA
    Urol Oncol; 2017 Dec; 35(12):694-700. PubMed ID: 29146441
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Sequencing CTLA-4 blockade with cell-based immunotherapy for prostate cancer.
    Wada S; Jackson CM; Yoshimura K; Yen HR; Getnet D; Harris TJ; Goldberg MV; Bruno TC; Grosso JF; Durham N; Netto GJ; Pardoll DM; Drake CG
    J Transl Med; 2013 Apr; 11():89. PubMed ID: 23557194
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Current status of immunological approaches for the treatment of prostate cancer.
    Drake CG; Antonarakis ES
    Curr Opin Urol; 2012 May; 22(3):197-202. PubMed ID: 22328018
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Prospects and limitations of recombinant poxviruses for prostate cancer immunotherapy.
    Hwang C; Sanda MG
    Curr Opin Mol Ther; 1999 Aug; 1(4):471-9. PubMed ID: 11713762
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Immunotherapeutics in development for prostate cancer.
    Harzstark AL; Small EJ
    Oncologist; 2009 Apr; 14(4):391-8. PubMed ID: 19342474
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A Randomized, Double-blind, Phase II Trial of PSA-TRICOM (PROSTVAC) in Patients with Localized Prostate Cancer: The Immunotherapy to Prevent Progression on Active Surveillance Study.
    Parsons JK; Pinto PA; Pavlovich CP; Uchio E; Kim HL; Nguyen MN; Gulley JL; Jamieson C; Hsu P; Wojtowicz M; Parnes H; Schlom J; Dahut WL; Madan RA; Donahue RN; Chow HS
    Eur Urol Focus; 2018 Sep; 4(5):636-638. PubMed ID: 30197041
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Promising novel immunotherapies and combinations for prostate cancer.
    Arlen PM; Mohebtash M; Madan RA; Gulley JL
    Future Oncol; 2009 Mar; 5(2):187-96. PubMed ID: 19284377
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Prostate cancer immunotherapy.
    McNeel DG
    Curr Opin Urol; 2007 May; 17(3):175-81. PubMed ID: 17414515
    [TBL] [Abstract][Full Text] [Related]  

  • 49. PROSTVAC® targeted immunotherapy candidate for prostate cancer.
    Shore ND
    Immunotherapy; 2014; 6(3):235-47. PubMed ID: 24762070
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Combination immunotherapy with prostatic acid phosphatase pulsed antigen-presenting cells (provenge) plus bevacizumab in patients with serologic progression of prostate cancer after definitive local therapy.
    Rini BI; Weinberg V; Fong L; Conry S; Hershberg RM; Small EJ
    Cancer; 2006 Jul; 107(1):67-74. PubMed ID: 16736512
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Refining Immuno-Oncology Approaches in Metastatic Prostate Cancer: Transcending Current Limitations.
    Wong RL; Yu EY
    Curr Treat Options Oncol; 2021 Jan; 22(2):13. PubMed ID: 33433743
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Enhancing immune responses to tumor-associated antigens.
    Higgins JP; Bernstein MB; Hodge JW
    Cancer Biol Ther; 2009 Aug; 8(15):1440-9. PubMed ID: 19556848
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The evolving role of immunotherapy in prostate cancer.
    Gerritsen WR
    Ann Oncol; 2012 Sep; 23 Suppl 8():viii22-7. PubMed ID: 22918924
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Intensifying tumour immunity through combination therapy.
    Dranoff G
    Lancet Oncol; 2012 May; 13(5):440-2. PubMed ID: 22326921
    [No Abstract]   [Full Text] [Related]  

  • 55. Emerging Immunotargets and Immunotherapies in Prostate Cancer.
    Montironi R; Santoni M; Sotte V; Cheng L; Lopez-Beltran A; Massari F; Matrana MR; Moch H; Berardi R; Scarpelli M
    Curr Drug Targets; 2016; 17(7):777-82. PubMed ID: 26898309
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Combinatorial treatments including vaccines, chemotherapy and monoclonal antibodies for cancer therapy.
    Baxevanis CN; Perez SA; Papamichail M
    Cancer Immunol Immunother; 2009 Mar; 58(3):317-24. PubMed ID: 18704409
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Advances in specific immunotherapy for prostate cancer.
    Kiessling A; Füssel S; Wehner R; Bachmann M; Wirth MP; Rieber EP; Schmitz M
    Eur Urol; 2008 Apr; 53(4):694-708. PubMed ID: 18061335
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Melanoma and immunotherapy.
    Eggermont AM; Schadendorf D
    Hematol Oncol Clin North Am; 2009 Jun; 23(3):547-64, ix-x. PubMed ID: 19464602
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial.
    Madan RA; Mohebtash M; Arlen PM; Vergati M; Rauckhorst M; Steinberg SM; Tsang KY; Poole DJ; Parnes HL; Wright JJ; Dahut WL; Schlom J; Gulley JL
    Lancet Oncol; 2012 May; 13(5):501-8. PubMed ID: 22326924
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Upcoming innovations in lung cancer immunotherapy: focus on immune checkpoint inhibitors.
    Aspeslagh S; Marabelle A; Soria JC; Armand JP
    Chin Clin Oncol; 2015 Dec; 4(4):48. PubMed ID: 26730760
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.